Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
11,549,491
-
Number of holders
-
40
-
Total 13F shares, excl. options
-
3,031,054
-
Shares change
-
-84,102
-
Total reported value, excl. options
-
$12,488,021
-
Value change
-
-$296,992
-
Put/Call ratio
-
67%
-
Number of buys
-
12
-
Number of sells
-
-9
-
Price
-
$4.12
Significant Holders of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) as of Q2 2023
46 filings reported holding TXMD - TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share as of Q2 2023.
TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) has 40 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3,031,054 shares
of 11,549,491 outstanding shares and own 26% of the company stock.
Largest 10 shareholders include Rubric Capital Management LP (1,192,191 shares), Clearline Capital LP (455,372 shares), VANGUARD GROUP INC (385,248 shares), Tejara Capital Ltd (369,594 shares), BlackRock Inc. (137,127 shares), MORGAN STANLEY (133,728 shares), GEODE CAPITAL MANAGEMENT, LLC (81,781 shares), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (52,726 shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (42,000 shares), and GABELLI FUNDS LLC (31,000 shares).
This table shows the top 40 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.